Dengue Survey Form | Dengue Survey

- Step 1 of 5

Please respond to the questions below by providing data in the respective cells or putting x in the respective cells (for multiple option questions).

Please elaborate on your responses as relevant.

Date of survey completion *

Respondent's title *

Name *

First

Last

Institution / Hospital / Affiliation *

Job title/ capacity *

Section 1

1. Who are the main stakeholders in the healthcare system related to infectious disease prevention and monitoring? *

2. Who are the main stakeholders in the healthcare system related to vaccination programmes implementation and monitoring? *

Section 2

3. To the best of your knowledge, what is the current dengue epidemiological situation like in the Dominican Republic in the following aspects: Please indicate the source of information where applicable"*

3.i. Prevalence of dengue infection: *

3.ii. Incidence of dengue infection: *

3.iii. Prevalence of severe dengue: *

3.iv. Incidence of severe dengue: *

3.v. Hospitalisation rate due to dengue: *

3.vi. Mortality rate due to dengue: *

4. What provinces have reported the highest burden of dengue in the Dominican Republic? *

5. To the best of your knowledge, what percentage of patients with dengue infection are receiving care in the public vs. the private healthcare system?*

5.i. % of patients with dengue infection who are receiving care in the public healthcare system: *

5.ii. % of patients with dengue infection who are receiving care in the private healthcare system: *

6. Is the distribution of patients the same for patients with dengue infections that require hospitalisation? If not, indicate accordingly below.*

6.i. % of patients with dengue infection who are hospitalised in the public hospitals: *

6.ii. % of patients with dengue infection who are hospitalised in the private hospitals: *

7. To the best of your knowledge, what percentage of patients with dengue infection are receiving care in primary care clinics (e.g. GP) vs. specialist clinics?*

7.i. % of patients with dengue infection who are receiving care in primary care clinics: *

7.ii. % of patients with dengue infection who are receiving care in specialists clinics: *

8. Are you aware of any epidemiological dengue-related studies /real-world evidence studies /registry studies being conducted in the Dominican Republic recently? *

8.i. If yes, please provide any publicly available details: *

8.ii. What is the overall level of interest of researchers to participate in real-world evidence studies? *

Section 3

9. Were there any changes in the past 5 years in the Dominican Republic related to the following aspects? *

9.i. If yes, please specify: *

Dengue surveillance system
Laboratory testing procedures for dengue infection
Dengue vector control measures
Dengue infection diagnosis criteria and classification E.g. definition of dengue cases, severe cases

10. Are you aware of any planned future changes in the Dominican Republic related to the following aspects? *

10.i. If yes, please specify: *

Dengue surveillance system
Laboratory testing procedures for dengue infection
Dengue vector control measures
Dengue infection diagnosis criteria and classification E.g. definition of dengue cases, severe cases

11. Are you familiar with the Sistema Nacional de Vigilancia Epidemiológica (SINAVE) database? If yes, please fill in the fields below *

If yes, please fill in the details below:*

11.i.i. What level data of is collected in this database? E.g. national, regional, or hospital *

11.i.ii. What is the timeframe of data in this database? E.g. from May 2005 to present, from 2010 to 2018 *

11.i.iii. What is the frequency of data entry? E.g. As and when cases are diagnosed and reported, once every 3 months *

11.i.iv. What is the methodology of data collection? E.g. extrapolate from EMR, direct HCP reporting, laboratory reporting *

11.i.v. Are you aware of any changes in the way cases are defined or data is being collected during the data availability period? *

11.i.v.i. If yes, please specify: *

11.i.vi. What proportion of the population is covered by this database? *

11.i.vii. Based on your judgement, how representative of the overall population is the data in this database? (SELECT ONE AND ELABORATE) *

11.i.viii.i. Sufficiently representative
11.i.viii.ii. Somewhat representative
11.i.viii.iii. Not representative Please specify what these discrepancies are coming from E.g. private hospitals, certain regions, primary care clinics are less represented
11.i.viii.iv. Other, please specify:

11.i.vii.i. Please elaborate *

11.i.vii.ii. Please elaborate *

11.i.vii.iii. Please elaborate and specify what these discrepancies are coming from E.g. private hospitals, certain regions, primary care clinics are less represented *

11.i.vii.iv. Please elaborate *

11.i.viii. What variables are collected within this database? E.g. demographics, date of diagnosis, severity, hospitalisation *

11.i.ix. Based on your judgement, what percentage of data in this database is incorrect or missing? *

11.i.x. What is the time lag between data collection and data being available for analysis? E.g. April 2023 data will be reported in July 2023 and will be publicly available in September 2023 *

11.i.xi. Is it possible to link this database with any other database? *

11.i.xi.i. If yes, please specify the database and how they can be linked *

11.i.xii. Would you recommend using this database for real-world studies? Please elaborate if needed *

11.i.xiii. Database is publicly accessible *

11.i.xiv. Database is accessible only via collaboration with academic institutions or hospitals *

11.i.xv. Database is NOT accessible for research sponsored by the pharmaceutical industry (even with collaboration) *

Is NOT
Is

11.i.xvi. Access to the database requires approval from a public agency, such as MoH *

11.i.xvi.i. If yes, please specify the approval process and how long does it take to complete the application to gain access *

11.i.xvii. Access to the database does NOT require payment of an access fee *

Does NOT
Does

11.i.xvii.i. If database does require payment, please specify the estimated amount or range of access fees: *

11.i.xviii. Any other comments: *

11.i.xix. Only a proportion of data is accessible *

11.i.xix.i. If yes, please specify: *

11.i.xx. Only data from a limited timeframe is accessible *

11.i.xx.i. If yes, please specify *

11.i.xxi. Data cannot be transferred out of the institution /database location and analysis must be run onsite *

11.i.xxi.i. If yes, please specify: *

11.i.xxii. Data cannot be transferred out of the country and analysis must be run in the Dominican Republic. *

11.xxii.i. If yes, please specify:

11.i.xxiii. If you know of any other limitations, please specify: *

11.i.xxiv. Are there any limitations in the types of research that can be conducted with the data from this database? *

11.i.xxiv.i. If yes, please specify: *

11.i.xxv. Are you aware of any recent examples of database studies in collaboration with /sponsored by the pharmaceutical industry? *

11.i.xxv.i. If yes, please provide any publicly available details: *

12. Are you aware of any other databases? *

12.i. Database name *

12.i.i. What level data of is collected in this database? E.g. national, regional, or hospital *

12.i.ii. What is the timeframe of data in this database? E.g. from May 2005 to present, from 2010 to 2018 *

12.i.iii. What is the frequency of data entry? E.g. As and when cases are diagnosed and reported, once every 3 months *

12.i.iv. What is the methodology of data collection? E.g. extrapolate from EMR, direct HCP reporting, laboratory reporting *

12.i.v. Are you aware of any changes in the way cases are defined or data is being collected during the data availability period? If yes, please specify *

12.i.v.i. If yes, please specify: *

12.i.vi. What proportion of the population is covered by this database? *

12.i.vii. Based on your judgement, how representative of the overall population is the data in this database? (SELECT ONE AND ELABORATE) *

12.i.viii.i. Sufficiently representative
12.i.viii.ii. Somewhat representative
12.i.viii.iii. Not representative Please specify what these discrepancies are coming from E.g. private hospitals, certain regions, primary care clinics are less represented
12.i.viii.iv. Other, please specify:

12.i.vii.i.i Please elaborate: *

12.i.vii.ii.i. Please elaborate: *

12.i.vii.iii.i. Please elaborate: *

12.i.vii.iv.i. Please elaborate: *

12.i.viii. What variables are collected within this database? E.g. demographics, date of diagnosis, severity, hospitalisation *

12.i.ix. Based on your judgement, what percentage of data in this database is incorrect or missing? *

12.i.x. What is the time lag between data collection and data being available for analysis? E.g. April 2023 data will be reported in July 2023 and will be publicly available in September 2023 *

12.i.xi. Is it possible to link this database with any other database? *

12.i.xi.i. If yes, please specify the database and how they can be linked: *

12.i.xii. Would you recommend using this database for real-world studies? Please elaborate if needed *

12.i.xiii. Database is publicly accessible *

12.i.xiv. Database is accessible only via collaboration with academic institutions or hospitals *

11.i.xv. Database is NOT accessible for research sponsored by the pharmaceutical industry (even with collaboration) *

Is NOT available
Is available

12.i.xvi. Access to the database requires approval from a public agency, such as MoH *

12.i.xvi.i. If yes, please specify the approval process and how long does it take to complete the application to gain access *

12.i.xvii. Access to the database does NOT require payment of an access fee *

Does NOT
Does

12.i.xvii.i. If database does require payment, please specify the estimated amount or range of access fees: *

12.i.xviii. Any other comments: *

12.i.xix. Only a proportion of data is accessible *

12.i.xix.i. If yes, please specify: *

12.i.xx. Only data from a limited timeframe is accessible *

12.i.xx.i. If yes, please specify: *

12.i.xxi. Data cannot be transferred out of the institution /database location and analysis must be run onsite *

12.i.xxi.i. If yes, please specify: *

12.i.xxii. Data cannot be transferred out of the country and analysis must be run in the Dominican Republic. *

12.i.xxii.i. If yes, please specify: *

12.i.xxiii. If you know of any other limitations, please specify: *

12.i.xxiv. Are there any limitations in the types of research that can be conducted with the data from this database? *

12.i.xxiv.i. If yes, please specify: *

12.i.xxv. Are you aware of any recent examples of database studies in collaboration with /sponsored by the pharmaceutical industry? *

12.i.xxv.i. If yes, please provide any publicly available details: *

13. Are you aware of any other databases? *

13.i. Database name *

13.i.i. What level data of is collected in this database? E.g. national, regional, or hospital *

13.i.ii What is the timeframe of data in this database? E.g. from May 2005 to present, from 2010 to 2018 *

13.i.iii. What is the frequency of data entry? E.g. As and when cases are diagnosed and reported, once every 3 months *

13.i.iv. What is the methodology of data collection? E.g. extrapolate from EMR, direct HCP reporting, laboratory reporting *

13.i.v. Are you aware of any changes in the way cases are defined or data is being collected during the data availability period? If yes, please specify *

13.i.v.i. If yes, please specify: *

13.i.vi. What proportion of the population is covered by this database? *

13.i.vii. Based on your judgement, how representative of the overall population is the data in this database? (SELECT ONE AND ELABORATE) *

13.i.viii.i. Sufficiently representative
13.i.viii.ii. Somewhat representative
13.i.viii.iii. Not representative Please specify what these discrepancies are coming from E.g. private hospitals, certain regions, primary care clinics are less represented
13.i.viii.iv. Other, please specify:

13.i.vii.i.i. Please elaborate: *

13.i.vii.i.ii. Please elaborate: *

13.i.vii.i.iii. Please elaborate: *

13.i.vii.i.iv. Please elaborate: *

13.i.viii. What variables are collected within this database? E.g. demographics, date of diagnosis, severity, hospitalisation *

13.i.ix. Based on your judgement, what percentage of data in this database is incorrect or missing? *

13.i.x. What is the time lag between data collection and data being available for analysis? E.g. April 2023 data will be reported in July 2023 and will be publicly available in September 2023 *

13.i.xi. Is it possible to link this database with any other database? *

13.i.xi.i. If yes, please specify the database and how they can be linked *

13.i.xii. Would you recommend using this database for real-world studies? Please elaborate if needed *

13.i.xiii. Database is publicly accessible *

13.i.xiv. Database is accessible only via collaboration with academic institutions or hospitals *

13.i.xv. Database is NOT accessible for research sponsored by the pharmaceutical industry (even with collaboration) *

It NOT available
Is available

13.i.xvi. Access to the database requires approval from a public agency, such as MoH *

13.i.xvi.i. If yes, please specify the approval process and how long does it take to complete the application to gain access *

13.i.xvii. Access to the database does NOT require payment of an access fee *

Does NOT
Does

13.i.xvii.i. If database does require payment, please specify the estimated amount or range of access fees: *

13.i.xviii. Any other comments: *

13.i.xix. Only a proportion of data is accessible.

13.i.xix.i. If yes, please specify: *

13.i.xx. Only data from a limited timeframe is accessible *

13.i.xx.i. If yes, please specify: *

13.i.xxi. Data cannot be transferred out of the institution /database location and analysis must be run onsite *

13.i.xxi.i. If yes, please specify: *

13.i.xxii. Data cannot be transferred out of the country and analysis must be run in the Dominican Republic *

13.i.xxii.i. If yes, please specify: *

13.i.xxiii. If you know of any other limitations, please specify: *

13.i.xxiv. Are there any limitations in the types of research that can be conducted with the data from this database? *

13.i.xxiv.i. If yes, please specify: *

13.i.xxv. Are you aware of any recent examples of database studies in collaboration with /sponsored by the pharmaceutical industry? *

13.i.xxv.i. If yes, please provide any publicly available details: *

14. Are you aware of any other databases? *

14.i. Database name *

14.i.i. What level data of is collected in this database? E.g. national, regional, or hospital *

14.i.ii. What is the timeframe of data in this database? E.g. from May 2005 to present, from 2010 to 2018 *

14.i.iii. What is the frequency of data entry? E.g. As and when cases are diagnosed and reported, once every 3 months *

14.i.iv. What is the methodology of data collection? E.g. extrapolate from EMR, direct HCP reporting, laboratory reporting *

14.i.v. Are you aware of any changes in the way cases are defined or data is being collected during the data availability period? *

14.i.v.i. If yes, please specify: *

14.i.vi. What proportion of the population is covered by this database? *

14.i.vii. Based on your judgement, how representative of the overall population is the data in this database? (SELECT ONE AND ELABORATE) *

14.i.viii.i. Sufficiently representative
14.i.viii.ii. Somewhat representative
14.i.viii.iii. Not representative Please specify what these discrepancies are coming from E.g. private hospitals, certain regions, primary care clinics are less represented
14.i.viii.iv. Other, please specify:

14.i.viii.i.i. Please elaborate: *

14.i.viii.i.ii. Please elaborate: *

14.i.viii.i.iii. Please elaborate: *

14.i.viii.i.i. Please elaborate: *

14.i.viii. What variables are collected within this database? E.g. demographics, date of diagnosis, severity, hospitalisation *

14.i.ix. Based on your judgement, what percentage of data in this database is incorrect or missing? *

14.i.x. What is the time lag between data collection and data being available for analysis? E.g. April 2023 data will be reported in July 2023 and will be publicly available in September 2023 *

14.i.xi. Is it possible to link this database with any other database? *

14.i.xi.i. If yes, please specify the database and how they can be linked: *

14.i.xii. Would you recommend using this database for real-world studies? Please elaborate if needed *

14.i.xiii. Database is publicly accessible *

14.i.xiv. Database is accessible only via collaboration with academic institutions or hospitals *

14.i.xv. Database is NOT accessible for research sponsored by the pharmaceutical industry (even with collaboration) *

Is NOT available
Is available

14.i.xvi. Access to the database requires approval from a public agency, such as MoH *

14.i.xvi.i. If yes, please specify the approval process and how long does it take to complete the application to gain access *

14.i.xvii. Access to the database does NOT require payment of an access fee *

Does NOT
Does

14.i.xvii.i. If database does require payment, please specify the estimated amount or range of access fees: *

14.i.xviii. Any other comments: *

14.i.xix. Only a proportion of data is accessible *

14.i.xix.i. If yes, please specify: *

14.i.xx. Only data from a limited timeframe is accessible *

14.i.xx.i. If yes, please specify: *

14.i.xxi. Data cannot be transferred out of the institution /database location and analysis must be run onsite *

14.i.xxi.i. If yes, please specify *

14.i.xxii. Data cannot be transferred out of the country and analysis must be run in the Dominican Republic *

14.i.xxii.i. If yes, please specify: *

14.i.xxiii. If you know of any other limitations, please specify: *

14.i.xxiv. Are there any limitations in the types of research that can be conducted with the data from this database? *

14.i.xxiv.i. If yes, please specify: *

14.i.xxv. Are you aware of any recent examples of database studies in collaboration with /sponsored by the pharmaceutical industry? *

14.i.xxv.i. If yes, please provide any publicly available details: *

Section 4

15. Based on your understanding, which of the following describes the perceptions and acceptance of the general public towards vaccination most accurately in the Dominican Republic? (SELECT ONE) *

The majority of the general public has high acceptance of vaccination
There are mixed opinions towards vaccination
Only a small proportion of the general public has a high acceptance towards vaccination

16. Does that differ in any way for vaccines that are not included in the national immunisation programme (NIP)? (SELECT ONE) *

No
Yes, vaccines that are not included in the NIP are LESS likely to be accepted by the general public
Yes, vaccines that are not included in the NIP are MORE likely to be accepted by the general public
Other

16.i. If other, please elaborate: *

17. Does that differ in any way for the vaccines that are indicated for children vs. adolescents vs. adults? *

17.i. If yes, please specify *

18. What are some of the potential barriers when rolling out a new vaccine that could limit the robust generation of real-world evidence? (SELECT ALL THAT APPLY AND ELABORATE) *

Cultural or religious beliefs
Lack of available information on the efficacy and safety of the vaccine from reliable sources
Cost barriers when the vaccine is not reimbursed
Access to vaccination centers
Others

If others, please specify: *

Paragraph Text

Al de eerste minuten op https://luckicasino-nl.com maken duidelijk hoeveel zorg in het totaalpakket is gestoken. Verjaardagsbonussen zorgen voor een persoonlijke ervaring en worden door veel gebruikers gewaardeerd. Een cookiebanner informeert transparant over het gebruik van tracking-technologie. De mobiele zoekfunctie vindt elk spel binnen enkele seconden. Een eigen sectie is gereserveerd voor exclusieve premium-merken met bijzondere titels. Innovatieve game-show-wheel formats trekken veel nieuwe spelers naar de live sectie. Animaties worden subtiel ingezet en dragen bij aan de coherente sfeer. Apple Pay en Google Pay bedekken de mobiele betaalwereld volledig. Quest-systemen integreren spelmatige elementen in de normale casinobeleving. Zowel visueel als functioneel behoort het casino tot de volwassen adressen op de markt.